Publications by authors named "Mark Boaz"

Claim this Profile
I
Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Judith Kirstein, William Douglas, Manoj Thakur, Mark Boaz, Thomas Papa

BMC Infect Dis· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
Emmanuel Feroldi, Mark Boaz, Sutee Yoksan, Kulkanya Chokephaibulkit, Usa Thisyakorn

J Infect Dis· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, Usa Thisyakorn, Chitsanu Pancharoen, Mark Boaz

Vaccine· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Dong Soo Kim, Guy Houillon, Gwang Cheon Jang, Sung-Ho Cha, Soo-Han Choi, Mark Boaz

Hum Vaccin Immunother· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.
Eric Plennevaux, Arunee Sabchareon, Kriengsak Limkittikul, Pornthep Chanthavanich, Chukiat Sirivichayakul, Mark Boaz

Vaccine· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
Anthony M Byers, Ryan Broder, Kelly Haupfear, Tatyana M Timiryasova, Branda T Hu, Mark Boaz

Open Forum Infect Dis· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Joseph Torresi, Leon G Heron, Ming Qiao, Joanne Marjason, Laurent Chambonneau, Mark Boaz

Vaccine· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a tetravalent dengue vaccine in children in Latin America.
Luis Villar, Gustavo Horacio Dayan, José Luis Arredondo-García, Doris Maribel Rivera, Rivaldo Cunha, Mark Boaz

N Engl J Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Maria Rosario Capeding, Ngoc Huu Tran, Sri Rezeki S Hadinegoro, Hussain Imam H J Muhammad Ismail, Tawee Chotpitayasunondh, Mark Boaz

Lancet· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.
Li-Min Huang, Tzou-Yien Lin, Cheng-Hsun Chiu, Nan-Chang Chiu, Po-Yen Chen, Mark Boaz

Vaccine· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
Emmanuel Feroldi, Chitsanu Pancharoen, Pope Kosalaraksa, Kulkanya Chokephaibulkit, Mark Boaz

Pediatr Infect Dis J· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.
Matthew Bonaparte, Bashir Dweik, Emmanuel Feroldi, Claude Meric, Alain Bouckenooghe, Mark Boaz

BMC Infect Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
Gustavo H Dayan, Manoj Thakur, Mark Boaz, Carol Johnson

Vaccine· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Luis Á Villar, Doris M Rivera-Medina, José Luis Arredondo-García, Mark Boaz, Linda Starr-Spires

Pediatr Infect Dis J· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
Emmanuel Feroldi, Maria Rosario Capeding, Mark Boaz, Sophia Gailhardou, Claude Meric

Hum Vaccin Immunother· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
Emmanuel Feroldi, Chitsanu Pancharoen, Pope Kosalaraksa, Veerachai Watanaveeradej, Kerdpanich Phirangkul, Mark Boaz

Hum Vaccin Immunother· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, Usa Thisyakorn, Arunee Sabchareon, Chitsanu Pancharoen, Mark Boaz

Pediatr Infect Dis J· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Walter Jaoko, Etienne Karita, Kayitesi Kayitenkore, Gloria Omosa-Manyonyi, Susan Allen, Mark J Boaz

PLoS One· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
Eftyhia Vardas, Pontiano Kaleebu, Linda-Gail Bekker, Anwar Hoosen, Elwyn Chomba, Mark Boaz

AIDS Res Hum Retroviruses· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
Sandhya Vasan, Sarah J Schlesinger, Yaoxing Huang, Arlene Hurley, Angela Lombardo, Mark Boaz

PLoS One· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
Sandhya Vasan, Sarah J Schlesinger, Zhiwei Chen, Arlene Hurley, Angela Lombardo, Mark Boaz

PLoS One· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
Melissa D Simek, Wasima Rida, Frances H Priddy, Pham Pung, Emily Carrow, Mark Boaz

J Virol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
Mark J Boaz, Peter Hayes, Tony Tarragona, Laura Seamons, Andrew Cooper

Clin Vaccine Immunol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
Sanjay Mehendale, Jan van Lunzen, Nathan Clumeck, Jurgen Rockstroh, Eva Vets, Mark Boaz

AIDS Res Hum Retroviruses· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
Walter Jaoko, Frederick N Nakwagala, Omu Anzala, Gloria Omosa Manyonyi, Josephine Birungi, Mark Boaz

Vaccine· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis